Your position:m.limatoxi.com>>EN>>EN>>Formulation>>Japans First! The Recombinant Protein COVID-19 Vaccine Introduced by Takeda Has Been Approved For Marketing>> article
Japans First! The Recombinant Protein COVID-19 Vaccine Introduced by Takeda Has Been Approved For Marketing
Editor:xuezhe Clicks:0Date:2022-4-22 13:21:37
Keyword:COVID-19 Vaccine
Healthoo Information:
Japans First! The Recombinant Protein COVID-19 Vaccine Introduced by Takeda Has Been Approved For Marketing
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
  • The $100 billion COVID-19 drug market
  • Several Domestic New Crown Mrna Companies Turn To Developing Broad-Spe...
  • 5 Chinese Pharmaceutical Companies Authorized to Produce Key Ingredien...
  • New vaccine administration law issued
  • Domestic vaccine for polio licensed
  • China rules out vaccine death link
  • China bans Shenzhen hepatitis B vaccine
  • Chinese researchers developed H7N9 flu vaccin...
  • EV71 vaccine phase III trial got positive result
  • First hepatitis E vaccine hits market in...
    		•
    Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463
    Baidu
    map